PlacidWay teams with CellCenter to widen access to stem cell therapy in Slovakia

PlacidWay has partnered with CellCenter in Bratislava to connect international patients with regulated European stem cell and regenerative treatments. The deal targets people traveling from North America and Europe who are seeking personalized care for complex chronic conditions.

Why it matters: - The partnership gives international patients a more direct route to regulated stem cell and regenerative therapies in Europe. - The collaboration could make Slovakia a more visible destination for patients seeking treatments for chronic, systemic and degenerative conditions. - PlacidWay’s platform is designed to reduce friction for patients comparing options, coordinating care and communicating with providers.

What happened: - PlacidWay announced a partnership with CellCenter, a regenerative medicine clinic in Bratislava, Slovakia. - The companies said the network will give international patients structured access to stem cell therapies and other regenerative treatments. - The effort is aimed at patients from North America, Eastern Europe and Western Europe. - CellCenter has operated for more than a decade.

The details: - CellCenter uses human umbilical cord blood, umbilical cord mesenchymal stem cells and adipose-derived stem cells and exosomes. - The clinic builds individualized treatment plans for autism, neurological disorders including Parkinson’s disease and Alzheimer’s disease, cardiovascular conditions, autoimmune disease, orthopedic needs, traumatology and longevity protocols. - Patients receive initial diagnostics before multidisciplinary teams design treatment pathways. - Those pathways may combine stem cells, exosomes, hyperbaric oxygen therapy, red light therapy and nutritional support. - MUDr. Milan Hric serves as Medical Director and Expert Guarantor. - Hric has more than 30 years of clinical and surgical experience. - Hric’s background includes work as a Deputy Chief Physician and participation in United Nations military missions. - CellCenter says its treatments follow European Union safety and quality rules and use ethically sourced adult stem cells. - The clinic says its therapies are intended to release anti-inflammatory and anti-fibrotic signals that support tissue regeneration. - CellCenter says it holds an ISO quality and management certificate. - PlacidWay operates as a medical tourism marketplace and Platform as a Service. - PlacidWay says it connects patients with accredited medical centers and doctors in more than 60 countries. - PlacidWay’s platform includes education tools and secure end-to-end communication with providers. - PlacidWay says the platform helps patients compare treatment claims and access specialized care safely. the company's social channels

Between the lines: - The announcement positions regenerative medicine as part of a broader healthspan and longevity market, not just a niche injury-treatment category. - The partnership also reflects rising cross-border demand for therapies that some patients may not find available, or easily accessible, in their home countries. - Both companies are leaning on regulation, personalization and transparency as differentiators in a field that can draw skepticism.

What's next: - PlacidWay and CellCenter will direct patients through the digital platform into consultations and treatment planning. - CellCenter is likely to keep emphasizing regulated adult stem cell protocols and individualized care as it seeks more international patients. - The partnership may help expand Slovakia’s profile as a medical tourism hub for regenerative therapies.

The bottom line: - The deal links a global medical tourism marketplace with a Slovak regenerative clinic to make stem cell therapy easier to access for international patients seeking regulated care.